Search Results
Jan 12, 2026, 07:00 ET Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity
VK2735 dosed weekly for 78 weeks. The VANQUISH-1 study has completed enrollment of approximately 4,650 adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study is enrolling approximately
More news about: Viking Therapeutics, Inc.
Jan 08, 2026, 14:00 ET Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
PsA with data supporting a potential comprehensive treatment approach alongside an incretin therapy for patients who also have obesity (BMI ≥30 kg/m²) or overweight (BMI 27-29.9 kg/m²) with at least one weight-related conditionINDIANAPOLIS, Jan.
More news about: Eli Lilly and Company
Jan 08, 2026, 07:00 ET Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity
VK2735 dosed weekly for 78 weeks. The VANQUISH-1 study has completed enrollment of approximately 4,650 adults with obesity (BMI ≥30 kg/m2) or who are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study is enrolling approximately
More news about: Viking Therapeutics, Inc.
Jan 05, 2026, 08:30 ET MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
tolerability, PK, and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese but otherwise healthy adults with a body mass index (BMI) of 30–45 kg/m². Nine subjects in each cohort were randomized in a 6:3 ratio, with each subject receiving either 4 weekly administrations of DA-1726
More news about: MetaVia Inc.
Dec 31, 2025, 08:07 ET The End of Shots? 5 Biotech Stocks Rethinking Diabetes
of 23% body weight when evaluating the treatment effect if all patients stayed on treatment, with 54% of patients with obesity at baseline reaching BMI below 30 kg/m2 at week 68. The trial included 3,417 adults with 87.4% of patients on steroids at baseline successfully tapering to prednisone 5 mg per
More news about: USA News Group
Dec 30, 2025, 08:00 ET OTO Fertility Launches World's First AI-Powered Platform & Wearable for Predictive Reproductive Insight
"Fertility Zone." The OTO Fertility Index™ is a more accurate indicator of pregnancy success than the current standard of care measurements including age, BMI, or AMH."Until now, there's been no accurate way to predict fertility outcomes based on what's actually happening in the body in real time," said
More news about: OTO Fertility
Dec 24, 2025, 21:05 ET Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies
conducted at multiple centers in the United States. The study is expected to enroll approximately 120 subjects with obesity (BMI > 30) or overweight (BMI > 27) with comorbidities.The study will evaluate the efficacy, safety, and tolerability of CBL-514 in combination with Zepbound®
More news about: Caliway Biopharmaceuticals
Dec 22, 2025, 18:03 ET FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults
placebo-controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with one or more weight-related comorbidities.1 People with diabetes were excluded.1
More news about: NOVO NORDISK INC.
Dec 18, 2025, 08:00 ET Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomized,
More news about: NOVO NORDISK INC.
Dec 18, 2025, 08:00 ET Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management
semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomized,
More news about: NOVO NORDISK INC.
Dec 18, 2025, 06:59 ET Viatris Provides Pipeline Update on Four Regulatory Milestones
ContraceptionThe investigational treatment is a once-weekly transdermal contraceptive patch being developed for women of childbearing potential with a BMI below 30 kg/m² who are appropriate candidates for combined hormonal contraception and who prefer a non-invasive, reversible option with a lower estrogen
More news about: Viatris Inc.
Dec 17, 2025, 19:00 ET Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
profiles, and liver enzyme levels, demonstrating GCG's advantages. Notably, compared to western populations, Chinese population typically have lower BMI (body mass index) but exhibit a more pronounced prevalence of central obesity. Mazdutide effectively addresses this by suppressing hepatic fat synthesis
More news about: Innovent Biologics
Dec 17, 2025, 09:07 ET Cerapedics Announces Publication in Spine of 24-Month ASPIRE Study Results of PearlMatrix™ P-15 Peptide Enhanced Bone Graft
enrolled 293 patients, including approximately 60 percent of patients that were considered high-risk for non-union (i.e., patients with type 2 diabetes, BMI ≥ 30 and/or nicotine users)."The publication of the ASPIRE study results in Spine underscores the strength of our clinical data for PearlMatrix
More news about: Cerapedics Inc.
Dec 17, 2025, 09:00 ET Thryv Therapeutics Announces Positive Phase 1 Results of THRV-1268 in Obese Participants
recently completed Phase 1 clinical study evaluating THRV-1268 in obese participants (NCT07186946). In a dedicated cohort of obese participants (BMI > 30 kg/m2), individuals demonstrated absolute and placebo-corrected QTcF shortening from baseline following a single dose of THRV-1268.
More news about: Thryv Therapeutics Inc.
Dec 17, 2025, 06:30 ET BMI Imaging Attends MSACROA 2025 to Support Innovation in Admissions and Records Management
Walker, Account Executive at BMI. "MSACROA is a great opportunity to understand each school's challenges and show how thoughtful digitization can make their work faster, smoother, and more secure."About BMIEstablished in 1958 as Bay Microfilm Incorporated, BMI Imaging Systems embarked
More news about: BMI Imaging Systems, Inc.
Dec 17, 2025, 06:00 ET BMI Offers Accessibility on Demand™
View original content:https://www.prnewswire.com/news-releases/bmi-offers-accessibility-on-demand-302638145.htmlSOURCE BMI Imaging Systems, Inc.
More news about: BMI Imaging Systems, Inc.
Dec 11, 2025, 19:00 ET Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity
diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of:BMI ≥ 28 kg/m² (obesity); orBMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hyperglycemia, hypertension,
More news about: Innovent Biologics
Dec 11, 2025, 06:45 ET Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
mg, respectively, compared to 4.0% with placebo. These rates were highly correlated with baseline BMI and included discontinuations for perceived excessive weight loss. For patients with a baseline BMI ≥35, discontinuation rates due to adverse events were 8.8% and 12.1% for the 9 mg and 12 mg doses,
More news about: Eli Lilly and Company
Dec 10, 2025, 09:00 ET NEW RESEARCH SHOWS RO HELPS PATIENTS ACHIEVE WEIGHT LOSS AND SAFETY OUTCOMES CONSISTENT WITH CLINICAL TRIALS
and reported their weight at 68 weeks (±14 days). The sample was 67.9% women and had a mean age of 45.8 years, with a median baseline body mass index (BMI) of 32.3 kg/m² (IQR 30.2-35.5) and baseline median weight of 94.3 kg. At 68 weeks, 52.1% of patients were on a 2.4 mg dose of semaglutide.ResultsAmong
More news about: Ro
Dec 09, 2025, 09:03 ET CONSUMING TREE NUTS AS SNACKS REDUCES FOOD CRAVINGS AND IMPROVES DIET QUALITY IN MILLENNIALS AT RISK FOR METABOLIC SYNDROME
Medical Center conducted a randomized, parallel arm, dietary intervention study with 84 men and women, ages 22-36, most of whom had overweight or obesity (BMI 24.5 to 34.9 kg/m2) and at least one metabolic syndrome risk factor at baseline (abdominal obesity, elevated triglycerides, low HDL cholesterol, high
More news about: International Tree Nut Council Nutrition Research & Education Foundation
Dec 08, 2025, 04:40 ET Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight
trial comparing the efficacy and safety of ASC30 tablets 20 mg, 40 mg and 60 mg as monotherapy to placebo in participants with obesity (BMI ≥30.0 kg/m²) or overweight (BMI ≥27.0 kg/m²) with at least one weight-related comorbidity, who did not have diabetes. The trial randomized 125 participants across multiple
More news about: Ascletis Pharma Inc.
Dec 05, 2025, 08:31 ET Lemme Launches Lemme Burn Gummy for Daily Metabolic Health
formulated with Morosil Red Orange Extract, a clinically studied ingredient shown in numerous human clinical studies to support visceral fat loss, reduced BMI and improved body composition. It is paired with Black Ginger, traditionally used to support energy and metabolic activity, Chromium, Methylated B12
More news about: Lemme
Dec 04, 2025, 00:00 ET Fitterfly (a division of PB Health) Secures Patent for PGR Technology to Drive Better Diabetes Outcomes
trained on over 10,00,000 CGM data points, covering 1,21,000 meals, 2,800+ CGM sensors and 2,000+ unique users. It also factors in age, gender, HbA1c, BMI, heart rate, step counts, caloric expenditure, co-morbidities and multiple CGM-derived metrics to deliver accurate, personalized glucose predictions.
More news about: Fitterfly
Dec 02, 2025, 08:00 ET DarioHealth Far Exceeds 2025 New Client Target with 79 New Accounts Signed Year-to-Date
Officer. "With outcomes such as a 1.4% reduction in eHbA1c, a 38% reduction in blood pressure by one stage and an average 10% Body Mass Index (BMI) reduction among participants, we are showing that our platform doesn't just engage – it delivers. These evidence-based results are resonating strongly
More news about: DarioHealth Corp.
Dec 02, 2025, 05:00 ET Blood Test Shows Obesity Speeds Alzheimer's Development
between the BBMs and body mass index (BMI) and the three-way interaction between baseline obesity, time and BBMs. The researchers also validated the BBMs against the amyloid PET scans.Analysis of the BBMs and PET scan data demonstrated that at baseline, BMI was associated with lower BBMs and reduced
More news about: Radiological Society of North America (RSNA)